Rusan Pharma today launched a Rs 100 crore-R&D centre and specialised manufacturing unit for transdermal patches at Kandla Special Economic Zone (SEZ) in Gujarat. Founded in 1994, the company is engaged in de-addiction and pain management products in the domestic and international markets.
“We are setting up a R&D centre ‘Navin Saxena Research and Technology’ (NSRT), in association with Clinical research organisation – ‘Quest Care’ and a specialised manufacturing unit for transdermal patches at the Kandla SEZ,” Rusan Pharma Chairman Navin Saxena told PTI after inaugurating the centre here. “We are investing around Rs 200 crore in NSRT and QuestCare in the two phase programme by 2017, of which Rs 100 crore (are) already invested in phase I. It will be funded through internal accruals and bank loans. “Through this new facilities, India can enter the innovation drive for the niche categories targeted by NSRT as a participation of USD 375 million global licensing market,” he added.